Xanthinol nicotinate tablets 150mg, No. 60

• Obliterating atherosclerosis and vascular endarteritis of the lower extremities;

• diabetic angiopathy;

• retinopathy;

• acute thrombophlebitis of superficial and deep veins;

• post-thrombophlebitic syndrome;

• trophic ulcers of the lower extremities;

• bedsores; Meniere's syndrome;

• dermatoses associated with a disorder of vascular trophism;

• violation of cerebral circulation.

Administered orally after meals starting from 150 mg 3 times a day, if necessary, the dose is increased to 300-600 mg 3 times a day.

The tablets are taken without chewing.

As the patient's condition improves, the dose is reduced to 150 mg 2-3 times a day.

The course of treatment usually lasts at least 2 months.

A second course is possible after consulting a doctor.

One tablet

Active substance : xanthinol nicotinate - 0.15 g,

auxiliary substances (potato starch, milk sugar, low molecular weight polyvinylpyrrolidone, calcium stearate) to obtain a tablet weighing 0.23 g.

• Acute heart failure including acute myocardial infarction;

• chronic heart failure IIB-III degree;

• mitral stenosis;

• arterial hypertension;

• acute bleeding;

• pregnancy I trimester;

• peptic ulcer and 12 duodenal ulcer in the acute stage;

• acute renal failure;

• glaucoma;

• childhood;

• increased individual sensitivity to the components of the drug.

Trade name of the drug

Xanthinol nicotinate

International non-proprietary name

Xanthinol nicotinate

Dosage form

pills

Composition

One tablet

Active substance : xanthinol nicotinate - 0.15 g,

auxiliary substances (potato starch, milk sugar, low molecular weight polyvinylpyrrolidone, calcium stearate) to obtain a tablet weighing 0.23 g.

Description

Tablets of white or almost white color, flat-cylindrical with beveled and scored.

Pharmacotherapeutic group

Antiaggregative agent

ATX code

C04AD02

Pharmacodynamics:

The drug combines the properties of theophylline and nicotinic acid: it causes expansion of peripheral vessels, improves collateral circulation, improves oxygenation and tissue nutrition, enhances oxidative phosphorylation and synthesis of ATP. Xanthinol nicotinate improves cerebral circulation and reduces cerebral hypoxia. The drug also activates the processes of fibrinolysis and reduces platelet aggregation.

Indications:

• Obliterating atherosclerosis and vascular endarteritis of the lower extremities;

• diabetic angiopathy;

• retinopathy;

• acute thrombophlebitis of superficial and deep veins;

• post-thrombophlebitic syndrome;

• trophic ulcers of the lower extremities;

• bedsores; Meniere's syndrome;

• dermatoses associated with a disorder of vascular trophism;

• violation of cerebral circulation.

Contraindications:

• Acute heart failure including acute myocardial infarction;

• chronic heart failure IIB-III degree;

• mitral stenosis;

• arterial hypertension;

• acute bleeding;

• pregnancy I trimester;

• peptic ulcer and 12 duodenal ulcer in the acute stage;

• acute renal failure;

• glaucoma;

• childhood;

• increased individual sensitivity to the components of the drug.

Pregnancy and lactation:

In the second and third trimester of pregnancy and during lactation, the use of the drug is permissible only if there are absolute indications and close medical supervision.

Method of administration and dosage:

Administered orally after meals starting from 150 mg 3 times a day, if necessary, the dose is increased to 300-600 mg 3 times a day.

The tablets are taken without chewing.

As the patient's condition improves, the dose is reduced to 150 mg 2-3 times a day.

The course of treatment usually lasts at least 2 months.

A second course is possible after consulting a doctor.

Side effects:

Xanthinol nicotinate may cause dizziness; lowering blood pressure; general weakness; sensation of heat; tingling and redness of the skin of the upper body, especially the neck and head; nausea; anorexia; diarrhea. These symptoms usually disappear after 10-20 minutes, do not require special treatment and discontinuation of therapy with this drug. If undesirable effects not described in this manual appear and the above side effects increase during therapy with this drug, you should immediately inform your doctor about it.

With long-term administration in high doses, the drug causes a change in glucose tolerance, an increase in the activity of 'hepatic' transaminases of alkaline phosphatase, hyperuricemia.

Overdose:

The drug is of little toxicity. Acute overdose of xanthinol nicotinate is accompanied by arterial hypotension, general weakness, dizziness, tachycardia, abdominal pain and vomiting. When symptoms of an overdose appear, symptomatic therapy is prescribed.

Interaction:

To avoid a sharp drop in blood pressure, the drug should not be used simultaneously with antihypertensive drugs. Cannot be combined with therapy with MAO inhibitors strophanthin.

Special instructions:

Xanthinol nicotinate causes a 'nicotine-like' syndrome accompanied by hyperesthesia of the mucous membrane of the nose and mouth (exacerbates the sensitivity of the olfactory and taste receptors); therefore, the smell and taste of alcoholic beverages taken during therapy is perceived to be sharper and more perverted.

Impact on the ability to drive vehicles. Wed and fur .:

Large doses of the drug can cause dizziness, weakness and arterial hypotension; therefore, you should refrain from driving a motor vehicle and working with mechanisms.

Release form / dosage:

Tablets for 015 g.

Packaging:

There are 10 tablets in a blister or non-cellular packaging, 30 or 60 tablets in polymer jars. Each can or 3 6 blister strip packs, together with instructions for use, are placed in a cardboard box.

Storage conditions:

List B. In a dry, dark place inaccessible to children.

Shelf life:

3 years. Do not use after the expiration date.

Vacation conditions

On prescription